Introduction {#s0005}
============

Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease that causes significant pain and morbidity. The disease is characterized by recurrent inflammatory nodules, abscesses, and fistula formation in the intertriginous areas of the body ([@b0100], [@b0120]). The multifactorial pathophysiology of HS has led physicians to use many strategies in treatment, including hormonal medications, steroids, immunomodulatory therapies, and antibiotics in addition to surgical interventions ([@b0095]). Despite this approach, patients commonly need to trial several therapeutic agents and/or use a combination of medications to obtain meaningful clinical improvement in HS.

In response to the complex etiology of the disease and the lack of reliable pharmacotherapy, some groups have investigated more nontraditional therapies, including nutritional interventions such as the Mediterranean diet ([@b0005]) and off-label use of biologic and immunomodulatory drugs ([@b0060], [@b0065]). This research is essential to expand therapeutic options for patients, many of whom remain undertreated. Herein, we describe repurposing the well-known chemotherapeutic drug, methotrexate, and report a series of patients with HS who responded favorably to long-term methotrexate monotherapy.

Methods {#s0010}
=======

This study was approved by the Institutional Review Board at Beth Israel Deaconess Medical Center (BIDMC). We performed a single-center, retrospective chart review to evaluate patients with HS who were treated with methotrexate at BIDMC between 2000 and 2018. Patients were identified using search terms "hidradenitis suppurativa" or the corresponding International Classification of Diseases 9 or 10 codes 705.83 and L73.2, respectively, in conjunction with "methotrexate." Comorbidities, concurrent medications, demographics, HS disease severity, laboratory test values, methotrexate dose, and side effects were evaluated. HS disease severity was assessed using the HS Physician Global Assessment (HS PGA; ranging from 1 \[clear\] to 6 \[very severe\]), Hurley Staging (I--III), abscess count, fistula count, and inflammatory nodule count.

Two patients in this analysis were initiated on methotrexate by our group at an outside hospital and transitioned to our subspecialty clinic. For both, an HS PGA score and narrative description of disease activity were available, but detailed lesion counts were not. To account for this, both patients were conservatively estimated to have five inflammatory nodules and two abscesses at baseline. This estimation was based on their clinical examination notes prior to care transfer and the severe characterization of their disease at presentation ([Table 1](#t0005){ref-type="table"}).Table 1Characteristics of patients treated with methotrexate without biologics.Patient number1141518192021Age72376068355252SexFemaleFemaleFemaleMaleMaleFemaleMaleBody mass indexOverweightObeseMorbidly obeseOverweightNormalNormalNormalComorbiditiesCoronary artery disease, hirsutism, hyperlipidemiaAlopecia areata, acne vulgarisObesityCoronary artery disease, hyperlipidemia, hypertensionNodulocystic acne, pilonidal cyst, Raynaud\'s syndromeCarpal tunnel syndrome, depression, myofascial pain syndrome, pilonidal cystHerniated disk, osteoarthritis, pilonidal cystPrior failed treatmentsNot documentedAdalimumab (stopped in setting of new onset alopecia areata)Adalimumab (intralesional triamcinolone, red light photodynamic therapy, wide local excision to bilateral axillae)Not documentedAdalimumab (stopped due to neuropathy, clindamycin topical, doxycycline, intralesional triamcinolone, tetracycline)Adalimumab (stopped due to allergic reaction, clindamycin topical, oral contraceptive agents)CephalexinConcomitant medications for hidradenitis suppurativaMinocycline, prednisone, spironolactoneBenzoyl peroxide, clindamycin topical, spironolactoneClobetasol cream, spironolactoneMinocyclineAmoxicillin-clavulanateCephalexinNoneAreas involvedInguinal folds, perianal, perineumAxillae, inframammary inguinal folds, buttocksAxillae, inframammary, left inguinal foldButtocks, left inguinal fold, scrotumButtocks, inguinal folds, intergluteal cleft, perineumAxillae, left buttock, mons pubisRight axilla, buttocks, groin, intergluteal cleftHS PGA baselineSevereModerateModerateVery severeMildModerateVery severeHS PGA end of treatmentMinimalModerateModerateMinimalMildMildModerateInflammatory nodules baseline5[\*](#tblfn1){ref-type="table-fn"}455[†](#tblfn2){ref-type="table-fn"}231Inflammatory nodules end of treatment1420222Fistulas baselineNR10NR026Fistulas endNR100005Abscesses baseline2[\*](#tblfn1){ref-type="table-fn"}002[†](#tblfn2){ref-type="table-fn"}000Abscesses end of treatment0000000[^1][^2][^3]

Patients were further stratified on the basis of whether they received concomitant biologic therapy with methotrexate to control for biologic-induced improvement. Study data were collected and managed using REDCap electronic data capture tools hosted at BIDMC ([@b0035], [@b0030]). Wilcoxon signed rank tests were used to assess for significance with the *p*-value set at 0.05 a priori.

Results {#s0015}
=======

A total of 29 patients met our initial search criteria. Fourteen patients were excluded due to never starting methotrexate or lack of follow-up data. Fifteen patients met our inclusion criteria and had multiple follow-up visits at our institution. The mean age was 43.8 years (range, 24--72 years). Patients were predominantly female (n = 10; 66.7%), white (n = 10; 66.7%), and obese (average body mass index \[BMI\]: 31.4; [Table 2](#t0010){ref-type="table"}). The most frequently reported comorbidity was acne (n = 6), followed by cardiovascular disease (n = 5). The most common failed prior medications were systemic antibiotics (n = 11). Biologics were trialed and failed in 6 patients (methotrexate without biologics: n = 4; methotrexate with biologics: n = 2). The most common concomitant therapy with methotrexate were oral antibiotics (n = 9).Table 2Disease characteristics of patients with hidradenitis suppurativa treated with methotrexate.Methotrexate with biologics (n = 8)Methotrexate without biologics (n = 7)Combined (n = 15)Age (years)36.1352.5743.80Average body mass index33.9828.4431.39Race4 white, 3 black, 1 Asian6 white, 1 Hispanic10 white, 3 black, 1 Hispanic, 1 AsianSex2 male, 6 female3 male, 4 female5 male, 10 femaleAverage length of treatment (months)9.1314.5711.67Average cumulative dose (mg)468.44579.21520.10Average inflammatory nodules baseline5.633.57[\*](#tblfn3){ref-type="table-fn"}4.67[\*](#tblfn3){ref-type="table-fn"}Average inflammatory nodules end6.501.864.33Average fistulas baseline3.751.5[\*](#tblfn3){ref-type="table-fn"}2.79[\*](#tblfn3){ref-type="table-fn"}Average fistulas end3.001.002.07Average abscesses baseline0.630.57[†](#tblfn4){ref-type="table-fn"}0.60[†](#tblfn4){ref-type="table-fn"}Average abscesses end1.750.000.93Average HS PGA baseline4.253.864.40Average HS PGA end4.503.003.80[^4][^5][^6]

Seven patients received methotrexate without any concomitant biologic medications ([Table 1](#t0005){ref-type="table"}), and eight patients received methotrexate concomitantly with biologics (adalimumab: n = 6; infliximab: n = 1; ustekinumab: n = 1). On average, the group of patients on methotrexate without biologics was older and had a lower BMI than those treated concomitantly with biologics ([Table 2](#t0010){ref-type="table"}).

At baseline, all patients had an average HS PGA score of 4.4 ± 1.12 (mean ± standard deviation on a 1--6 scale; [Table 2](#t0010){ref-type="table"}). The average inflammatory nodule count was 4.67 ± 3.42, and the average number of fistulas was 2.79 ± 3.53 ([Table 2](#t0010){ref-type="table"}). The disease of patients receiving methotrexate without biologics was, on average, less severe than for those receiving methotrexate with biologics ([Table 2](#t0010){ref-type="table"}).

The modal initial dose of methotrexate was 10 mg/week (range, 7.5--20 mg). The average length of treatment (LOT) for all patients was 11.7 months (range, 1--38 months), and the mean cumulative dose of methotrexate was 520.13 mg (range, 30--1665 mg; [Table 1](#t0005){ref-type="table"}). Patients treated with methotrexate without biologics had a longer LOT and cumulative methotrexate dose (LOT: 14.6 months; dose: 579.21 mg) compared with those receiving concomitant biologics (LOT: 9.1 months; dose: 468.44 mg; [Table 2](#t0010){ref-type="table"}).

Overall, HS PGA scores decreased modestly, but not significantly (*p* = 1.00; [Table 2](#t0010){ref-type="table"}). Patients without biologics showed improvements in HS PGA scores, but those treated with biologics slightly worsened during the treatment course ([Table 2](#t0010){ref-type="table"}). The average number inflammatory nodules decreased in the methotrexate-without-biologics group (baseline: 3.57; final: 1.86; *p* = .38) and increased in patients treated with methotrexate and biologics (baseline: 5.63; final: 6.50; [Table 2](#t0010){ref-type="table"}). All abscesses in the methotrexate-without-biologics group (n = 4) resolved over the treatment course. There was no significant change in fistula count (*p* = .69).

Methotrexate was generally well tolerated. Five patients reported self-resolving gastrointestinal disturbances, and one patient had elevated alkaline phosphatase levels that did not interfere with treatment.

Discussion {#s0020}
==========

Methotrexate is an antimetabolite analog of folic acid that inactivates dihydrofolate reductase, an enzyme crucial to thymidine synthesis ([@b0050]). Historically, methotrexate has been used to treat cancer and autoimmune diseases, such as psoriasis and rheumatoid arthritis. Our hypothesis regarding methotrexate's efficacy in HS is partially rooted in its downregulation of neutrophil chemotaxis ([@b0010], [@b0085], [@b0115]).

HS is often characterized by leukocytosis, neutrophilia, pus drainage, and abscess and fistula formation ([@b0080]). Neutrophils are particularly abundant in the deep infiltrate of HS lesions ([@b0055]); therefore, methotrexate's effects on neutrophils may be particularly beneficial in treating patients with an abscess-predominant HS phenotype ([@b0040]). However, methotrexate's effect on neutrophils may not entirely explain its mechanism in HS. Colchicine, another anti-inflammatory medication that also decreases neutrophil chemotaxis, does not appear to offer any benefit in patients with HS ([@b0105]).

Methotrexate has also been found to suppress NF-kB, a downstream tumor necrosis factor (TNF) alpha-activated inflammatory mediator and a known target of HS therapy ([@b0040]). Furthermore, methotrexate appears to decrease IL-17 levels in patients with psoriasis through enhancement of regulatory T-cell function ([@b0125]). Increased IL-17 has been identified in HS lesional skin, and reports of anti-IL-17 therapy effectiveness suggests that IL-17 modulation may affect HS disease progression ([@b0065], [@b0075], [@b0090]).

Despite these mechanistic explanations for its potential efficacy, methotrexate is not well described or often prescribed in HS. In an analysis of the National Ambulatory Medical Care Survey from 1990 to 2009 and the MarketScan Medicaid Database from 2003 to 2007, no patients received methotrexate for HS ([@b0020]). Improvement in a subset of patients in this analysis differs from the only other report of patients with HS treated with methotrexate, which demonstrated no improvement ([@b0045]). Importantly, the patients in that case series received methotrexate as a monotherapy and for a shorter period of time compared with ours, with one patient treated for 6 weeks, one for 4 months, and one for 6 months. A few case reports describe methotrexate use in combination with anti-TNF agents for patients with concurrent HS and synovitis, acne, pustulosis, hyperostosis, osteitis syndrome ([@b0015], [@b0025], [@b0110]). Importantly, methotrexate was primarily used for arthritis control, and skin symptoms did not improve until anti-TNF therapy was initiated. Therefore, an additional role may exist for methotrexate in increasing anti-TNF serum levels.

Baseline differences in the demographics of patients receiving methotrexate with and without biologics may inform therapeutic decisions. Methotrexate appeared most effective as a primary therapy in older patients with lower BMIs not receiving biologic therapy. Additionally, a dose response may be partially responsible for improvement because patients with a longer LOT and cumulative dose fared better in terms of disease severity. However, methotrexate does not appear to offer additional benefit in patients receiving biologic therapy. This is in contrast with findings in RA literature, where methotrexate administered concomitantly with anti-TNF enhanced clinical response and prolonged anti-TNF therapeutic levels ([@b0070]). Methotrexate's lack of additional benefit in this HS cohort is potentially due to the high baseline disease activity in this group, signaled by the addition of methotrexate to their therapeutic regimen in the first place.

Methotrexate's side effects are well established and include anemia and hepatotoxicity. All patients were screened with a baseline complete blood count, liver function tests, hepatitis panel, and tuberculosis serology prior to initiation. Complete blood counts and liver function tests were repeated 1 month after treatment initiation and every 3 months thereafter.

Conclusion {#s0025}
==========

Methotrexate may represent a viable primary therapy in a certain subset of patients with HS, but it appears ineffective in patients treated in conjunction with biologic therapies. Limitations of this study include its retrospective nature and small sample size. Future directions may include investigations of the use of methotrexate as a strict monotherapy, especially in patients not treated with biologics. Additionally, future studies may investigate the use of methotrexate in a more diverse patient population because patients in our cohort were predominantly white and female.
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[^1]: HS PGA, Hidradenitis Suppurativa Physician's Global Assessment; NR, not recorded.

[^2]: Conservative estimate based on the following narrative description: "Disease confined to perineum, perianal, and inguinal area. Numerous large plaques of indurated erythema and scarring."

[^3]: Conservative estimate based on the following narrative description: "Almost diffuse involvement and multiple interconnected sinus tracts and abscesses across the buttocks, and also involving the groin and scrotum."

[^4]: HS PGA, Hidradenitis Suppurativa Physician's Global Assessment.

[^5]: Assumed five inflammatory nodules for two patients (see footnote in [Table 1](#t0005){ref-type="table"} for more information).

[^6]: Assumed two abscesses for two patients (see footnote in [Table 1](#t0005){ref-type="table"} for more information).
